Myositis is a disorder in which the immune system attacks the muscles. It is hoped that this new treatment may help improve the symptoms of this disease.

Research Objectives

Status

Current

Recruitment

Open

Patient Group

Idiopathic Inflammatory Myopathy/Myositis Status: Current

Study location

Wesley Research Institute

Phase

3

Study type

Industry Sponsored

Sponsors: Argenx BV (global) and ICON Clinical Research Pty Ltd (Local)

    Lead investigator    
            Dr Daman Langguth        

        Clinical trial coordinator		
				Venita Bali			

Technical title

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathies

About this research project

The research project is testing a new treatment for Active Idiopathic Inflammatory Myopathy. This is a disorder in which the immune system attacks the muscles. This leads to muscle weakness and may affect other organs of the body.

The potential new treatment being tested is called efgartigimod (also called ARGX113). It is hoped that efgartigimod may help improve the symptoms of myositis.

Latest News

QSBC listed in the top 100 Innovators for 2024

Wesley Research Institute is celebrating the recognition of Dr Arutha Kulasinghe, Professor John Fraser, and Associate Professor Kirsty Short on their feature in The Australian Innovators magazine! Their groundbreaking research at Wesley Research Institute’s Queensland Spatial Biology Centre (QSBC) is paving the way for more tailored, effective pandemic preparedness solutions for future generations. Their project, […]

3D Illustration Concept of Human Circulatory System Heart Anatomy

New Wesley Research Institute Program Offers Hope for Pulmonary Hypertension Patients

A new and unique Pulmonary Hypertension (PH) Research Program at Wesley Research Institute aims to provide hope and improved quality of life for patients affected by this debilitating condition. The program aims revolutionise PH treatment by investigating new therapies, and supplementing existing ones to avoid the need for transplants.

QSBC Announces Latest Publications in Spatial Biology

The Queensland Spatial Biology Centre (QSBC) is proud to announce the publication of research papers in three highly regarded journals. These studies, all published in July 2024, highlight our innovative research in cancer and immunotherapy.

1 2 3 … 13 Next »

Rare Diseases

Testing treatments to improve symptoms of Myositis